Toxoplasmosis Testing Market to Surge at 6.40% CAGR Through 2031 - North America Leads 38% Share as Rapid Prenatal & Molecular Diagnostics Accelerate Worldwide| DataM Intelligence

Leander, Texas and Paris, France - Dec 03, 2025
According to DataM Intelligence, the global Toxoplasmosis Testing Market is estimated to reach at a CAGR of 6.40% from 2024 to 2031 . This steady growth is propelled by rising incidences of toxoplasmosis infections worldwide, increasing demand for effective serological and molecular testing methods, high prevalence in at-risk populations like pregnant women and immunocompromised individuals, major consumption of undercooked meat and contaminated water sources, growing awareness of congenital risks, and advancements in rapid diagnostic kits for early detection and treatment.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/toxoplasmosis-testing-market?sindhuri

Report Details:
• No. of Pages: 180
• Forecast Period: 2024-2031
• Compound Annual Growth Rate: 6.40%
• Regions Covered: Global

United States Recent Developments:

✅ Abbott Laboratories launched a point-of-care toxoplasmosis IgG/IgM rapid test kit in collaboration with CDC guidelines, enhancing screening in prenatal clinics and reporting 18% adoption in urban hospitals
✅ Bio-Rad expanded its ELISA-based toxoplasmosis assay portfolio with automated platforms for high-throughput labs, focusing on multiplex detection for immunocompromised patients
✅ Thermo Fisher Scientific introduced PCR-based amniotic fluid testing kits for congenital toxoplasmosis, integrated with NGS for variant analysis in pediatric diagnostics
Europe Recent Developments:

✅ BioMérieux developed EU-IVDR certified VIDAS® toxoplasmosis serology assays in France and Germany, aligning with EMA standards for sheep farming surveillance and prenatal screening
✅ DiaSorin S.p.A. rolled out enhanced chemiluminescent immunoassay kits for cerebrospinal fluid analysis in Italy and the UK, driven by rising ocular toxoplasmosis cases in migrant populations
✅ Gold Standard Diagnostics launched affordable lateral flow assays for clinics in Scandinavia, supporting WHO-aligned programs for immigrant health monitoring and early intervention

Buy Now and Enjoy a 30% Year-End Discount: https://www.datamintelligence.com/buy-now-page?report=toxoplasmosis-testing-market?sindhuri

Competitive Landscape
The market features strong competition between global diagnostics giants, specialized immunoassay providers, and innovative molecular testing firms.

1. Abbott Laboratories leads with 13.2% global market share, strengthened by advanced TORCH screening panels and large diagnostics distribution channels.
2. Thermo Fisher Scientific follows closely with 12.7% share, driven by high-sensitivity molecular kits and PCR-based toxoplasma detection systems.
3. bioMérieux holds 11.4% share, leveraging automated immunoassay platforms across hospitals and reference labs.
4. Bio-Rad Laboratories captures 10.6% market share, supported by ELISA assays for IgG & IgM detection and global lab collaborations.
5. Diasorin S.p.A. secures 9.8% share, dominating CLIA-based toxoplasmosis testing modules integrated into prenatal diagnostics.
6. ACON Laboratories accounts for 8.4% share, driven by rapid point-of-care toxoplasma test kits in developing regions.
7. Biokit holds 7.2% share, specializing in confirmatory testing solutions for blood banks.
8. Elitech Group owns 6.5% share, growing via OEM supply of automated assay reagents.
9. Bionote records 5.9% share, popular in veterinary toxoplasma diagnostics with multiplex antibody kits.
10. Atlas Medical captures 4.8% share, supported by cost-effective serology test kits for emerging markets.
11. LifeSpan BioSciences holds 4.3% share, focused on toxoplasma antibodies and recombinant antigen distribution for research labs.
12. Gold Standard Diagnostics registers 3.8% share, driven by its FDA-cleared toxoplasmosis ELISA line.
13. Genemedi Suzhou Biotechnology maintains 3.4% share, expanding strongly in Asia through recombinant proteins and antigen test kits.

✦ Upcoming High-Growth Players - Set to Transform the Market

Technological innovation and partnerships in prenatal testing & molecular diagnostics are driving new entrants:
14. Vircell Diagnostics (Spain) - Estimated 2.6% emerging share through multiplex real-time PCR toxoplasmosis panels.
15. Euroimmun (Germany) - Estimated 2.3% emerging share with AI-enhanced automated serology systems for TORCH screening.
16. InBios International (U.S.) - Estimated 1.9% emerging share driven by R&D around rapid tests for low-resource settings.
17. NovaTec Immundiagnostica (Germany) - Estimated 1.6% emerging share, expected to grow with CE-approved toxoplasmosis microplate assays.

Speak to Our Analyst and Get Customization in the Report: https://www.datamintelligence.com/customize/toxoplasmosis-testing-market?sindhuri

Segmentation Analysis

By Test Type
• Serological Tests represents the largest segment with 60% revenue share in 2023, projected to grow at 6.8% CAGR, valued for high sensitivity in IgG/IgM detection, cost-effectiveness in routine screening, versatility for prenatal and veterinary use, effective performance in population surveillance, and widespread adoption in hospitals and labs requiring non-invasive, scalable diagnostics across at-risk groups and endemic regions.Molecular Tests (PCR) shows steady growth with 40% revenue share in 2023, expected to grow at 5.7% CAGR, preferred for confirmatory accuracy, rapid turnaround, and applications in amniotic fluid analysis with moderate volume requirements.

By Sample Type
• Blood Sample commands the largest share with 70% revenue share in 2023, growing at 6.5% CAGR, driven by ease of collection, urbanization in outpatient testing, growing demand for seroprevalence studies, essential need for antibody profiling in pregnant women, and rising accessibility across diagnostic centers and home kits. Amniotic Fluid shows robust growth with 15% revenue share in 2023, expanding at 6.2% CAGR, valued for fetal infection specificity in high-risk pregnancies. Cerebrospinal Fluid demonstrates significant applications with 15% revenue share in 2023 for neurological complications.

By End-User
• Hospitals lead the market with 50% revenue share in 2023, growing at 6.7% CAGR, driven by integrated prenatal care, urbanization in maternal health services, growing toxoplasmosis awareness in ERs, essential role in confirmatory diagnostics, and rising policy support across public and private facilities.
• Diagnostic Laboratories shows accelerated growth with 30% revenue share in 2023, expected to grow at 6.3% CAGR, preferred for high-throughput processing and research collaborations. Clinics demonstrate consistent presence with 20% revenue share in 2023.

Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription?sindhuri

Regional Analysis:
» North America holds the largest market share with 38% revenue share in 2023, driven by advanced healthcare systems, high prenatal screening rates, stringent CDC guidelines, and substantial R&D in multiplex diagnostics across the United States and Canada.

» Asia-Pacific emerges as the fastest-growing region, projected to expand at 7.2% CAGR through 2031, fueled by high prevalence in tropical areas, massive population-driven testing needs, increasing urbanization and meat consumption, growing public health initiatives, and investments in affordable kits across China, India, Southeast Asia, and other emerging markets.

Market Trends & Drivers
The Toxoplasmosis Testing Market is experiencing steady growth driven by infectious disease surveillance enhancements, maternal health priorities, diagnostic technology advancements, and global prevalence concerns. Key trends include the development of point-of-care rapid kits, growth of multiplex PCR-ELISA combinations, advancement in non-invasive sampling methods, expansion of veterinary-human one-health integrations, and increasing focus on AI-assisted result interpretation and supply chain resilience. The epidemiological evolution, innovation in assays, and prevention requirements are significantly contributing to market growth.

Related Reports:
1. Paget's Disease Market -
https://www.datamintelligence.com/download-sample/pagets-disease-market?sindhuri
2. Erosive Hand Osteoarthritis Market - https://www.datamintelligence.com/download-sample/erosive-hand-osteoarthritis-market?sindhuri
3. Febrile Neutropenia Treatment Market-
https://www.datamintelligence.com/download-sample/febrile-neutropenia-treatment-market?sindhuri

Contact Us:
Sai Kiran
DataM Intelligence 4 market Research LLP
Phone: +1 877-441-4866
Email: Sai.k@datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specialises in strategic reports that guide businesses in high-growth sectors such as diagnostics and infectious disease innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.

This release was published on openPR.